The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Increase to Block Listing

21 Jan 2021 14:49

RNS Number : 5100M
MaxCyte, Inc.
21 January 2021
 

 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

 

Increase to Block Listing,

 

Block Listing Return

 

and

 

Total Voting Rights

 

 

 

MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that application has been made for admission to trading on AIM in respect of an additional block listing of 942,900 common stock of $0.01 each in the capital of the Company ("Common Stock") to become effective on 27 January 2021.

 

The Common Stock may be issued pursuant to the exercise of share options under the Company's Long-Term Incentive Plan (the "LTIP") and will, upon issue, rank pari passu in all respects with the Company's existing Common Stock. Following this increase, the total Block Listing will consist of 1,000,000 Common Stock.

 

 

AIM Block Admission Return

 

MaxCyte also makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.  

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From: 1 July 2020 To: 21 January 2021

 

d. Number and class of securities not issued under scheme

 

319,263 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

262,163 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

57,100 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional block listing application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

 

The total issued stock capital of the Company is 77,422,169 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 67,522,080 and the number of restricted shares of Common Stock trading under the symbol 'MXCS' is 9,900,089.  

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

+1 301 944 1660

 

Date

 

21 January 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUMCGUPGGCG
Date   Source Headline
5th Dec 20227:00 amRNSSigning of Strategic Platform License
2nd Dec 20225:22 pmRNSTotal Voting Rights
1st Dec 20227:00 amRNSNon-Executive Director Appointment
11th Nov 20227:00 amRNSHolding(s) in Company
10th Nov 20227:01 amRNSFiling of Form 10-Q
10th Nov 20227:00 amRNSMaxCyte Reports Third Quarter Financial Results
2nd Nov 202212:05 pmRNSParticipation in Upcoming Investor Conferences
1st Nov 20229:25 amRNSTotal Voting Rights
17th Oct 20222:58 pmRNSHolding(s) in Company
12th Oct 20221:00 pmRNSNotice of Third Quarter 2022 Financial Results
3rd Oct 20229:42 amRNSTotal Voting Rights and Block Listing Return
28th Sep 20221:05 pmRNSSigning of Strategic Platform License
21st Sep 20221:05 pmRNSNew Maryland headquarters
8th Sep 20227:00 amRNSMorgan Stanley Healthcare Conference Participation
1st Sep 20224:39 pmRNSTotal Voting Rights
11th Aug 20227:00 amRNSSecond Quarter and Half-Year Results
11th Aug 20227:00 amRNSFiling of Form 10-Q for Second Quarter
2nd Aug 20222:44 pmRNSTotal Voting Rights
20th Jul 202210:00 amRNSChange of Registered Office
15th Jul 20221:01 pmRNSNotice of Results
12th Jul 20221:01 pmRNSSigning of Strategic Platform License
12th Jul 20227:00 amRNSGrant of Options
8th Jul 20225:16 pmRNSHolding(s) in Company
1st Jul 20227:00 amRNSTotal Voting Rights
30th Jun 20227:00 amRNSResult of AGM
17th Jun 20222:51 pmRNSHoldings in Company
6th Jun 20227:00 amRNSPublication of Annual Report
27th May 20227:00 amRNSNotice of AGM
16th May 20227:00 amRNSInducement Grants
10th May 20227:00 amRNSFiling of Form 10-Q
10th May 20227:00 amRNSMaxCyte Reports First Quarter Financial Results
4th May 20227:00 amRNSUpcoming Investor Conferences
29th Apr 20222:41 pmRNSTotal Voting Rights
19th Apr 20227:00 amRNSInducement Grants Under Nasdaq Listing Rule 5635
13th Apr 20227:00 amRNSDeparture of CFO and Preliminary Q1 2022 Revenue
11th Apr 20227:00 amRNSHolding(s) in Company
1st Apr 20227:02 amRNSTotal Voting Rights
28th Mar 20221:19 pmRNSGrant of Options and PDMR Dealing
28th Mar 20227:00 amRNSGrant of Options and PDMR Dealing
23rd Mar 20227:00 amRNSFourth Quarter and Full Year Financial Results
10th Mar 20227:00 amRNSMaxCyte, Names Cenk Sumen Chief Scientific Officer
8th Mar 20222:29 pmRNSHolding(s) in Company
3rd Mar 20229:45 amRNSHolding(s) in Company
1st Mar 20227:00 amRNSBlock Listing Return
24th Feb 20221:00 pmRNSNotice of Results
22nd Feb 20223:56 pmRNSHolding(s) in Company
21st Feb 20227:00 amRNSConsolidation of Trading Lines
14th Feb 20221:00 pmRNSUpcoming Investor Conferences
14th Feb 20227:00 amRNSInducement Grants Under Nasdaq Listing Rule
1st Feb 20227:00 amRNSLicense with Intima Bioscience

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.